Converd forms a partnership with China Resources (CR Pharmaceutical) in developing oncolytic virus therapy platform
Column：Company News
Time：2017-12-15
Converd has received investment in shares from CR Pharmaceutical(华润生命科学). This is a part of Converd’s B series financing, which also includes investments from Nanjing Jingyong Healthcare Capitals.
Converd has received investment in shares from CR Pharmaceutical(华润生命科学). This is a part of Converd’s B series financing, which also includes investments from Nanjing Jingyong Healthcare Capitals. In September 2017, Converd and CR Pharmaceutical signed an agreement on establishing R & D platform of oncolytic virus therapy. The partnership is committed to developing novel oncolytic viral and cell therapy for cancers, and translation to pharmaceutical manufactures and clinical applications of oncolytic viral and cellular therapy.
The above content is reproduced from ：http://mp.weixin.qq.com/s/wVFlNaokMMFRpPAUcjMA6g
detail《CHINA RESOURCES INVESTS IN CONVERD》